Short answer
Adicet Bio Inc (ACET) filed an 8-K current report with the SEC on September 28, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). Positive safety and efficacy data announced for prula-cel in systemic lupus erythematosus, including patients with lupus nephritis.
Adicet Bio Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Positive safety and efficacy data announced for prula-cel in systemic lupus erythematosus, including patients with lupus nephritis
- Preliminary Phase 1 data webcast scheduled for September 28, 2026
- Clinical update could influence prula-cel’s development prospects and Adicet’s valuation
Item 8.01 · Other Events
- Preliminary Phase 1 data: 50% of evaluable lupus nephritis patients achieved complete renal response at 12 months
- 54% achieved DORIS remission, with all 12-month responses ongoing through 12 to 21 months except one
- Safety profile supports outpatient dosing: no DLTs, IEC-HS, ICANS, or GvHD; Grade 1-2 CRS in 25%
- All patients discontinued immunosuppressants, while all but one tapered steroids to 5 mg prednisone equivalent or less
- FDA alignment enables pivotal lupus nephritis study planning, with start-up activities targeted for Q4 2026 and potential non-renal SLE expansion
Item EX-99.1 · Exhibit EX-99.1
- Phase 1 data support prula-cel advancement toward pivotal lupus nephritis testing, with start-up activities planned for 4Q 2026
- At 12 months, 54% achieved DORIS remission and 50% of evaluable lupus nephritis patients achieved complete renal response
- All patients discontinued immunosuppressants, while all but one reduced steroids to ≤5 mg prednisone equivalent daily
- Safety profile supports outpatient dosing: no CRS above Grade 2, IEC-HS, ICANS, dose-limiting toxicities or GvHD
- FDA discussions may enable pivotal-study expansion into non-renal SLE, potentially broadening prula-cel’s addressable market beyond lupus nephritis
Item EX-99.2 · Exhibit EX-99.2
- Interim Phase 1 data showed 50% 12-month complete renal response and 54% DORIS remission among 22 efficacy-evaluable LN/SLE patients
- Treatment-free benefit: all patients discontinued immunosuppressants, while all but one tapered steroids to ≤5 mg prednisone equivalent
- Favorable safety signal: no IEC-HS, ICANS, or greater-than-Grade-2 CRS observed across 24 safety-evaluable patients
- Immune-reset evidence: undetectable CD19+ B cells in 22/22 evaluable patients, followed by naïve B-cell recovery
- Regulatory catalyst: FDA-aligned single-arm pivotal LN study, potentially up to 90 patients, with interim data anticipated in 2028 and readout in 2029
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Adicet Bio Inc 8-K filings
Get the next ACET 8-K as it lands
Follow ACET for push alerts, or ask the research agent what this filing means.